- More than 1.6 million new diabetes patients are accounted for each year in the U.S.
- Around 7.8% of the American population currently have some form of diabetes.
- DreaMed is backed by leading medical experts Yale-New Haven Health and FDA approved.
- DreaMed systems works on MD Logic-based algorithms.
Diabetes has been a global epidemic for years, costing the United States government more than half of their $174 billion medical expenditure for the treatment of the disease. A survey has shown that more than 22% of hospital inpatients were being treated or incurred either Type 1 or Type 2 diabetes. American citizens are among the most prevalent for Type 2 diabetes, currently, more than 23 million Americans have some form of diabetes, a tally of more than 7.8% of the U.S. population.
In the U.S. alone, more than 1.6 new diabetes cases are accounted for each year. With the lack of access to endocrinologists, with estimates around one endocrinologist per 41,000 patients, DreaMed, an Israeli biotech startup has now pushed the boundaries on what Artificial Intelligence (AI) can do for the treatment and monitoring of diabetes. To help mitigate the lack of access to proper health care and diabetes-related medical staff, the startup, which was founded in 2014 has already received FDA approval for its Advisor Pro patent and is set to be used in some of America’s premier children’s hospitals. We explore the work done by DreaMed, and how the new frontier of diabetes treatment will be AI.
Who is DreaMed?
DreaMed is a leading Israeli biotech startup founded in 2014, focusing on creating software and technology that can improve and monitor the treatment for Type 1 and Type 2 diabetes via its fully AI-integrated diabetes management platform. This platform will allow patients better access to diabetes medical staff and information, creating a more equal and transparent system that enables patients from any corner of the globe to access it.
DreaMed Diabetes Management Platforms
The DreaMed Advisor Pro platform has recently received approval from the United States Food and Drug Administration and will be rolled out in premier children’s hospitals across the country.
How it works
Using the patient’s unique treatment regimen, data is collected and securely stored using the patient’s CGM, SMBG and insulin pump. From there, the allocated data is then organized with the assistance of MD Logic-based algorithms, a system developed by some of the world’s leading clinicians and endocrinologists. The platform sets out to create a therapeutic plan for each individual, based on their insulin monitoring needs which can now eliminate complexities in the monitoring process of both the patient and the health care professional.
Advisor Pro
Years of clinical trials and field testing of the platform has enabled DreaMed to assist patients with Type 1 diabetes. But the recent developments and advancements in clinical research have seen the company reach new frontiers with Advisor Pro, expanding to the recommended treatment of Type 2 diabetes patients. Advisor Pro has been seen to improve the quality of life for patients, but help to significantly reduce hospitalization administrative costs and procedures. The use of Advisor Pro makes it easier, affordable, and more economically viable for patients and clinicians to adapt to the use of AI-based medical platforms.
Clinically Supported
DreaMed has built a reputable reputation among some of America’s high-profile medical professionals. They’ve created lasting relationships with leading medical institutions such as Yale-New Haven Health, Texas Children’s Hospital, and the University of Florida. The recent approval by the FDA has seen the company collaborate with high-ranked children’s hospitals, which can now fast-track the use of its systems and provide access to professional and trusted health care for millions of patients.
The takeaway
DreaMed saw an opportunity to uplift and improve the health care system through the use of Artificial Intelligence. Their systems have been tested by various endocrinologist experts and clinical researchers. The use of Advisor Pro has seen a decrease in hospital admissions for diabetic patients, with the use of software from leading companies such as Medtronic Diabetes, DexCom, Yale-New Haven, and Glooko. DreaMed has become a trusted diabetes management platform for patients and providers, allowing those in need access to a management system that can help monitor and track Type 1 and 2 diabetes treatment.
